METHODS: In this retrospective study, we investigated whether there was a difference in the clinical outcomes of non-GCB DLBCL cases (n = 97) that were confirmed by immunochemistry to demonstrate high levels of Bcl-2 protein expression (>50% neoplastic cells stained) when compared to those who were deemed negative based on this criterion. Response to rituximab-based induction immunochemotherapy, five-year progression-free survival, and five-year overall survival were assessed.
RESULTS: There was no statistically significant difference in response to treatment, five-year progression-free survival, or five-year overall survival between the patients who were positive for Bcl-2 (n = 70) compared to those who were considered Bcl-2 negative (n = 27).
CONCLUSIONS: High levels of Bcl-2 protein expression do not appear to be of prognostic significance in non-GCB DLBCL and therefore Bcl-2 may not be a key therapeutic target in the treatment and improvement of clinical outcome in such cases.
方法:在这项回顾性研究中,我们调查了非GCB型DLBCL病例(n=97)的临床结局是否与根据该标准被认为阴性的病例相比,通过免疫化学证实显示高水平的Bcl-2蛋白表达(>50%肿瘤细胞染色)存在差异.对基于利妥昔单抗的诱导免疫化疗的反应,5年无进展生存期,并评估5年总生存率.
结果:对治疗的反应没有统计学上的显着差异,5年无进展生存期,或与Bcl-2阴性患者(n=27)相比,Bcl-2阳性患者(n=70)的5年总生存率。
结论:Bcl-2蛋白的高水平表达在非GCBDLBCL中似乎没有预后意义,因此Bcl-2可能不是治疗和改善此类病例临床结果的关键治疗靶标。